Greg Conn

Title: The Innovative Contributions of Greg Conn

Introduction

Greg Conn is a notable inventor based in Madrid, Spain. He has made significant contributions to the field of biotechnology, particularly in dendritic cell therapy. With a total of 3 patents, Conn's work focuses on enhancing immune responses through innovative methods.

Latest Patents

One of Conn's latest patents is titled "Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy." This invention covers the use of specific classes of lipids, including cationic lipids, in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing, and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways. Antigen uptake via cationic lipid by dendritic cells results in a significant reduction in the population of immune suppressive regulatory T cells in tumors and a notable increase in tumor-targeting cytotoxic T-cells. The loss of regulatory T cells and the increase of tumor-specific cytotoxic cells are conducive to the effective elimination of tumors.

Career Highlights

Throughout his career, Greg Conn has worked with PDS Biotechnology Corporation, where he has contributed to advancing therapeutic strategies in immunology. His innovative approaches have positioned him as a key figure in the development of dendritic cell therapies.

Collaborations

Conn has collaborated with notable professionals in the field, including Frank Bedu-Addo and Martin Ward. Their combined expertise has furthered the impact of Conn's inventions in the biotechnology sector.

Conclusion

Greg Conn's innovative work in dendritic cell therapy and his contributions to biotechnology highlight his role as a leading inventor in the field. His patents reflect a commitment to enhancing immune responses and improving therapeutic outcomes.